Inhibitors of cyclin-dependent kinases 4/6 for breast cancer patients with different somatic mutations of the PIK3CA gene

Inhibitors of cyclin-dependent kinases 4/6 for breast cancer patients with different somatic mutations of the PIK3CA gene

Introduction. Breast cancer is the leader in cancer incidence in theRussian Federation. The tumor is considered extremely heterogeneous and the luminal subtypes of breast tumors occupy a special place, since they are considered relatively favorable in therapy and control of the disease.Drug therapy...

Full description

Bibliographic Details
Main Authors: A. F. Nasretdinov, N. I. Sultanbaeva, Sh. I. Musin, O. N. Lipatov, A. A. Izmailov, R. T. Ayupov, K. V. Menshikov, A. V. Pushkarev, A. V. Sultanbaev
Format: Article
Language:Russian
Published: Remedium Group LLC 2020-12-01
Series:Медицинский совет
Subjects:
endocrine therapy
metastatic cancer
breast
pik3ca
luminal subtype
cdk4/6 inhibitors
alpelisib
Online Access:https://www.med-sovet.pro/jour/article/view/5933

Internet

https://www.med-sovet.pro/jour/article/view/5933

Similar Items